Absci Boosts AI-Powered Drug Discovery With Oracle And AMD Collaboration
1. Absci partners with Oracle and AMD for AI-driven drug discovery. 2. New tech accelerates biologics design cycles and model training. 3. Stock increases 10.50% to $2.63 following the announcement. 4. Collaboration provides high-performance infrastructure for large-scale simulations.